Financings in Brief: Genzyme
This article was originally published in The Gray Sheet
Executive Summary
Genzyme: Firm's Genzyme Tissue Repair division receives $10 mil. "for general corporate purposes" from sister division Genzyme General "in exchange for an increase of one million Tissue Repair designated shares," the firm states. The designated shares "are not issued or outstanding" but may be held or sold by the Genzyme board of directors "from time to time for the benefit of Genzyme General without allocating any consideration to Genzyme Tissue Repair," or may be distributed "as a stock dividend to holders of Genzyme General common stock." Parent firm Genzyme retains an option, valid until June 15, 1998, to "allocate an additional $10 mil." from Genzyme General to Genzyme Tissue Repair "in exchange for an increase in Tissue Repair designated shares at the rate of $10 per share," Genzyme says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.